<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>临床试验时事评论 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-01T11:20:06+08:00</updated>
  <subtitle>临床试验相关评论 临床试验前沿信息</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>妄议规章丨CN-GCP2020与ICH-GCP差异的解读（2）——谈谈CRO概念差异</title>
    <updated>2020-07-05T17:56:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-07-05:/s/AzFS17tmL3EL5KcUlMvIeA</id>
    <link href="https://mp.weixin.qq.com/s/AzFS17tmL3EL5KcUlMvIeA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>超赞！PPIs口服肠溶制剂BE试验等效困难的探究及对策（上篇）</title>
    <updated>2020-06-25T22:54:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-06-25:/s/8gAJkw9nliMaaRjSOyGnfw</id>
    <link href="https://mp.weixin.qq.com/s/8gAJkw9nliMaaRjSOyGnfw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>妄议规章丨CN-GCP2020与ICH-GCP差异的解读（1）——试验前签署ICF</title>
    <updated>2020-06-22T21:59:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-06-22:/s/uVMzaio5iFTK-JGv1c1KWw</id>
    <link href="https://mp.weixin.qq.com/s/uVMzaio5iFTK-JGv1c1KWw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>特殊注射剂BE怎么做，看这篇就够了…</title>
    <updated>2020-06-04T13:22:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-06-04:/s/97oHaXNNft5cVQj4CUft3A</id>
    <link href="https://mp.weixin.qq.com/s/97oHaXNNft5cVQj4CUft3A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>乱弹系列丨谈谈被政策摁死在地板上的新三类化药</title>
    <updated>2020-03-15T19:17:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-03-15:/s/M-IHvkB7vQ7oM90bVFRexQ</id>
    <link href="https://mp.weixin.qq.com/s/M-IHvkB7vQ7oM90bVFRexQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>数据管理规范-从临床试验的角度浅谈数据可靠性</title>
    <updated>2020-03-07T19:48:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-03-07:/s/09O3zEl9woOXsrEz393rlw</id>
    <link href="https://mp.weixin.qq.com/s/09O3zEl9woOXsrEz393rlw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>法规解读丨从天晴布地奈德混悬液的批准看吸入制剂临床审评大势</title>
    <updated>2020-03-01T20:50:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-03-01:/s/e7heXQo360DTsaFsu3OkJg</id>
    <link href="https://mp.weixin.qq.com/s/e7heXQo360DTsaFsu3OkJg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗特发性肺纤维化（IPF）新药临床试验的介绍</title>
    <updated>2020-02-22T11:48:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-02-22:/s/IbnuFX_-7OXHViM2R07D4Q</id>
    <link href="https://mp.weixin.qq.com/s/IbnuFX_-7OXHViM2R07D4Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>指南解析 丨缓控释制剂是否一定要开空腹及餐后BE？</title>
    <updated>2019-02-08T23:07:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2019-02-08:/s/MnpbaKLzxce2wTVbhauUHg</id>
    <link href="https://mp.weixin.qq.com/s/MnpbaKLzxce2wTVbhauUHg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>法规解读丨新GCP征求意见稿的建议及意见（4）————第三章 伦理委员会</title>
    <updated>2018-10-28T00:03:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2018-10-28:/s/UdhlF0DvFsvXYgyfe1yZHQ</id>
    <link href="https://mp.weixin.qq.com/s/UdhlF0DvFsvXYgyfe1yZHQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>